Welcome to PrEP Watch, a clearinghouse for information on pre-exposure prophylaxis (PrEP) for HIV prevention. PrEP Watch includes information on data, additional research, cost, access and advocacy efforts in the United States and across the globe.

Resources to Understand PrEP

PrEP is a new and emerging HIV prevention intervention in which HIV-negative individuals take an antiretroviral (ARV) to reduce their individual risk of acquiring HIV. More here.

PrEP Data to-Date

A number of large-scale trials from a range of populations and in different areas of the world have generated data showing that daily oral TDF/FTC (Truvada) is safe and effective to reduce the risk of HIV infection for HIV-negative people. More here.


Guidelines for prescribing and using PrEP are available from a range of groups, including state health departments in the US, the US Centers for Disease Control (CDC) and national-level clinician groups as well as guidelines on international demonstration projects from the World Health Organization. More here.

Implementing PrEP in the “Real World”

Depending on location, communities are at varying stages of implementing PrEP. In the US the Food and Drug Administration (FDA) has approved daily Truvada for HIV prevention, and some communities in the US are exploring how it might best be delivered. Outside of the US, Truvada as PrEP is not approved by local regulators and in most cases remains inaccessible outside of research studies. Country-specific information is being collected. More here.

Cost, Access and Using PrEP

There is a growing body of information on how to access PrEP and how its cost can be covered in the US. There is limited access elsewhere outside of clinical trials or demonstration projects. More here.

Ongoing research

At the same time, additional clinical trial research is ongoing to test new regimens—twice-weekly, for example—and different ARVs, like maraviroc. More here.

Local Advocacy

Advocacy efforts supporting both the PrEP research pipeline and PrEP access for populations most in need are active in areas around the world. More here

Other HIV Prevention Research

PrEP is just one element of the ARV-based and wider biomedical HIV prevention agenda, which include a range of proven approaches and others under study. More here.

Quick Links

What’s new

Preliminary results from Ipergay study show high adherence

Data presented at the 2014 International AIDS Conference showed detectable drug levels in more than 80% of participants in the trial of intermittent PrEP in men who have sex with men.

iPrEx OLE reports full protection for participants taking four or more doses per week, partial protection from lower adherence

Data presented at the International AIDS Conference showed overall protection of 49% and promising demand for and adherence to PrEP among the men who have sex with men and transgender women in the open label extension

New Momentum on PrEP, But Critical Needs Are Overlooked

AVAC’s Mitchell Warren lauds the WHO’s new guidelines and calls on the organization to do more

NMAC launches new PrEPare for Life awareness campaign

Check out the new videos, training manual and more.

#PrEPat2years commemorates FDA decision

Two years after Truvada was indicated for prevention by the Food and Drug Administration, advocacy groups are taking to social media to highlight progress and challenges that remain.

NYTimes explores estimates of PrEP efficacy

In Is Truvada, the Pill to Prevent H.I.V., 99 Percent Effective? Don’t Be So Sure, Josh Barro discusses the modeling that produced this number.